FDA granted expanded labeling approval for Boston Scientific's PFA System, with the company anticipating further regulatory approvals in Japan and China.
1 report, 0 independent
Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted expanded labeling approval for Boston Scientific's PFA System, with the company anticipating further regulatory approvals in Japan and China.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices
- Japan
Related events
- FDA clearance enables market entry into the U.S. for an unnamed company, which is also navigating the long-term regulatory process in Japan.
- FDA and Pfizer are seeking regulatory approval for their products.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
Coverage
Newest first; wire copies grouped- Unknown outlet